23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation

Key Takeaways Explain This Topic AI

Sepsis-3 defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, identified clinically by an acute increase in total Sequential Organ Failure Assessment (SOFA) score of >=2 points above baseline, which conveys an in-hospital mortality exceeding 10%.

Septic shock represents a subset of sepsis with profound circulatory, cellular, and metabolic abnormalities, defined clinically by persistent hypotension requiring vasopressors to maintain MAP >=65 mmHg AND a serum lactate >2.0 mmol/L (18 mg/dL) despite adequate volume resuscitation, carrying hospital mortality >40%.

The Surviving Sepsis Campaign (SSC) 2021 1-Hour Bundle prioritizes immediate serum lactate measurement (re-measured in 2-4 hours if >2.0 mmol/L), obtaining >=2 sets of blood cultures prior to antimicrobials without delaying therapy >45 minutes, administering broad-spectrum IV antimicrobials within 1 hour, and infusing 30 mL/kg of balanced crystalloids within 3 hours for hypotension or lactate >=4.0 mmol/L.

Balanced crystalloids (Lactated Ringer's or Plasma-Lyte) are superior to 0.9% normal saline based on the landmark SMART and SALT-ED randomized trials, demonstrating statistically significant reductions in hyperchloremic metabolic acidosis, acute kidney injury, and new renal replacement therapy.

Norepinephrine is the first-line vasopressor of choice (superior to dopamine per the SOAP II trial); Vasopressin at a fixed, non-titratable dose of 0.03 units/min is the preferred second-line adjunct to spare adrenergic exposure; and stress-dose IV Hydrocortisone (200 mg/day) is indicated strictly for refractory septic shock requiring escalating vasopressor support.

Last updated: September 2026

Sepsis-3 Consensus Definitions & Pathophysiology

Sepsis is a medical emergency that accounts for more than one-third of all in-hospital deaths. Historically defined by the Systemic Inflammatory Response Syndrome (SIRS) criteria, modern critical care management adheres to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , which abandoned SIRS due to its poor specificity and lack of association with organ damage.

Modern Sepsis-3 Definitions

Sepsis : Life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinically, organ dysfunction is operationalized as an acute increase in total Sequential Organ Failure Assessment (SOFA) score of ≥2 points attributable to the infectious insult. A SOFA score increase of ≥2 points is associated with an in-hospital mortality rate exceeding 10% .

Septic Shock : A lethal subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are profound enough to substantially increase mortality. Septic shock is clinically identified by the persistence of both:

Persistent hypotension requiring vasopressors to maintain a mean arterial pressure ( MAP ) ≥65 mmHg; AND

A serum lactate >2.0 mmol/L (18 mg/dL) despite adequate volume resuscitation.

This specific combination carries an in-hospital mortality rate exceeding 40% .

Pathophysiological Cascade

The pathophysiology of sepsis involves a complex interplay between pathogen-associated molecular patterns (PAMPs) and host pattern-recognition receptors (e.g., Toll-like receptors). This triggers an uncontrolled systemic release of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), leading to:

Diffuse Endothelial Barrier Disruption : Loss of the endothelial glycocalyx and opening of inter-endothelial tight junctions, resulting in massive capillary leak, extravasation of albumin and intravascular water into the interstitial space, and severe hypovolemia.

Microvascular Thrombosis & Heterogeneity : Activation of tissue factor, downregulation of thrombomodulin and protein C, and impaired fibrinolysis produce widespread microvascular thrombi. Capillary beds display functional shunting, where unperfused capillaries sit adjacent to perfused ones, causing regional cellular hypoxia.

Mitochondrial Dysfunction (Cytopathic Hypoxia) : Pro-inflammatory mediators and reactive nitrogen/oxygen species impair mitochondrial oxidative phosphorylation, leading to a state of cytopathic dysoxia where cells cannot utilize oxygen despite adequate macrovascular delivery. This stimulates anaerobic glycolysis and systemic hyperlactatemia.

Profound Peripheral Vasodilation : Overproduction of inducible nitric oxide synthase (iNOS) yields excessive nitric oxide (NO), causing vascular smooth muscle relaxation and refractory distributive shock.

The Sequential Organ Failure Assessment (SOFA) Score

The SOFA score evaluates acute dysfunction across six major organ systems on a graded 0 to 4 scale. A baseline score of zero is assumed in patients without preexisting chronic organ failure.

Organ System Clinical Parameter SOFA 0 SOFA 1 SOFA 2 SOFA 3 SOFA 4
Respiration PaO2 / FiO2 ratio (mmHg) ≥400 <400 <300 <200 with mechanical vent <100 with mechanical vent
Coagulation Platelet count (×10³/µL) ≥150 <150 <100 <50 <20
Liver Total Bilirubin (mg/dL) <1.2 1.2 – 1.9 2.0 – 5.9 6.0 – 11.9 ≥12.0

Cardiovascular Mean Arterial Pressure (MAP) or Vasopressor Support MAP ≥70 mmHg MAP <70 mmHg Dopamine ≤5 or Dobutamine (any dose) Dopamine >5 OR Norepinephrine ≤0.1 OR Epinephrine ≤0.1 Dopamine >15 OR Norepinephrine >0.1 OR Epinephrine >0.1

Central Nervous Glasgow Coma Scale (GCS) 15 13 – 14 10 – 12 6 – 9 <6

Renal Creatinine (mg/dL) or Urine Output (mL/day) <1.2 1.2 – 1.9 2.0 – 3.4 3.5 – 4.9 or <500 mL/day ≥5.0 or <200 mL/day

The Quick SOFA (qSOFA) Score

To facilitate bedside screening outside the intensive care unit, the Sepsis-3 task force introduced qSOFA . It incorporates three easily assessable clinical variables (1 point each):

Respiratory rate ≥22 breaths/min ;
Altered mental status (Glasgow Coma Scale score <15);

Systolic blood pressure ≤100 mmHg .

Critical Clinical Distinction : A qSOFA score ≥2 indicates a high risk of prolonged ICU stay and in-hospital mortality. However, the Surviving Sepsis Campaign (SSC) 2021 guidelines specifically recommend against using qSOFA as a single screening tool for sepsis compared to SIRS, the National Early Warning Score (NEWS), or the Modified Early Warning Score (MEWS). This recommendation stems from extensive meta-analyses demonstrating that while qSOFA has high specificity (~96%), its sensitivity is unacceptably low (~50-60%), causing clinicians to miss or delay recognition of early sepsis.

Surviving Sepsis Campaign (SSC) 2021 1-Hour Bundle

The SSC guidelines emphasize rapid operational execution through the 1-Hour Resuscitation Bundle . Resuscitation must begin immediately upon recognition; all elements should ideally be initiated within the first hour of triage. SSC 2021 1-HOUR BUNDLE OVERVIEW

┌─────────────────────────────────────────────────────────────────┐
│ 1. MEASURE BLOOD LACTATE STAT │
│ • Re-measure within 2-4 hours if initial lactate >2.0 mmol/L │
├─────────────────────────────────────────────────────────────────┤
│ 2. OBTAIN BLOOD CULTURES PRIOR TO ANTIMICROBIALS │
│ • Minimum 2 sets (aerobic + anaerobic) │
│ • Do NOT delay antibiotics >45 minutes if access is delayed │
├─────────────────────────────────────────────────────────────────┤
│ 3. ADMINISTER BROAD-SPECTRUM IV ANTIMICROBIALS │
│ • Within 1 hour for shock or definite sepsis │
├─────────────────────────────────────────────────────────────────┤
│ 4. RAPID FLUID RESUSCITATION: 30 mL/kg BALANCED CRYSTALLOIDS │
│ • Within 3 hours for MAP <65, SBP <90, or Lactate >=4.0 │
│ • Lactated Ringer's / Plasma-Lyte preferred over 0.9% Saline │
├─────────────────────────────────────────────────────────────────┤
│ 5. APPLY VASOPRESSORS DURING OR AFTER RESUSCITATION │
│ • Maintain MAP >=65 mmHg (First-line: Norepinephrine) │
└─────────────────────────────────────────────────────────────────┘
Detailed Breakdown of Bundle Elements
1. Measure Blood Lactate Level

Serum lactate serves as a surrogate marker of tissue hypoperfusion, anaerobic glycolysis, and adrenergic stimulation. Normal levels are <2.0 mmol/L.

A lactate ≥4.0 mmol/L (36 mg/dL) mandates aggressive crystalloid resuscitation even if blood pressure appears normal (cryptic septic shock).

Serial Lactate Monitoring : If the initial lactate is elevated (>2.0 mmol/L), re-measure within 2 to 4 hours . Resuscitation targeting a lactate clearance of ≥10% to 20% every 2 hours is associated with significant survival benefits.

2. Blood Cultures Prior to Antimicrobials

Obtain at least two sets of blood cultures (each set consisting of one aerobic and one anaerobic bottle) via separate venipuncture sites.

In patients with indwelling vascular catheters in place for >48 hours, draw at least one set percutaneously and one set through each lumen of the catheter to evaluate for catheter-related bloodstream infections (differential time to positivity >2 hours indicates line source).

Crucial Rule : Do NOT delay antimicrobial therapy by more than 45 minutes if blood cultures cannot be promptly obtained.

3. Broad-Spectrum Empiric Antimicrobials

Administer broad-spectrum empiric IV antimicrobials within 1 hour of recognition for patients presenting with septic shock or high probability of sepsis.

For patients with possible sepsis without shock, conduct a rapid clinical evaluation within 3 hours: if infection remains likely, administer antimicrobials immediately.

Regimens must cover common Gram-positive (including MRSA when risk factors are present) and Gram-negative organisms (including Pseudomonas aeruginosa in high-risk hosts), such as Vancomycin PLUS Piperacillin-tazobactam, Cefepime, or Meropenem .

4. Rapid Fluid Resuscitation: The 30 mL/kg Rule

Administer an initial fixed volume of 30 mL/kg of IV crystalloid within the first 3 hours to patients presenting with:

Septic shock (hypotension requiring vasopressors or SBP <90 mmHg / MAP <65 mmHg); OR

Severe tissue hypoperfusion manifested by a serum lactate ≥4.0 mmol/L .

Dosing Caveat : In patients with severe obesity (BMI ≥30 kg/m²), calculate the 30 mL/kg bolus based on ideal body weight (IBW) rather than total actual body weight to prevent iatrogenic fluid overload.

5. Early Vasopressor Application

Initiate vasopressors during or immediately after fluid resuscitation if the patient remains hypotensive, targeting a MAP ≥65 mmHg .

Do not withhold vasopressors until the full 30 mL/kg fluid bolus has finished if diastolic arterial pressure is critically low (e.g., DBP <40 mmHg) or MAP is <50 mmHg; early norepinephrine infusion restores coronary and systemic perfusion while fluids infuse.

Fluid Resuscitation: Balanced Crystalloids versus 0.9% Normal Saline

One of the most consequential paradigm shifts in modern critical care is the abandonment of 0.9% normal saline in favor of balanced crystalloids (e.g., Lactated Ringer's or Plasma-Lyte).

The Physiological Problem with 0.9% Normal Saline

0.9% Sodium Chloride is unphysiological: it contains 154 mEq/L of sodium and 154 mEq/L of chloride (osmolality 308 mOsm/L), with a Strong Ion Difference (SID) of zero.

Rapid large-volume infusion of 0.9% saline produces hyperchloremic metabolic acidosis (normal plasma chloride is 98–106 mEq/L). The elevated chloride concentration displaces bicarbonate, causes renal afferent arteriolar vasoconstriction, reduces renal cortical blood flow, diminishes glomerular filtration rate, and promotes interstitial fluid extravasation.

The Balanced Crystalloid Solution

Lactated Ringer's (LR) : Contains 130 mEq/L Na, 109 mEq/L Cl, 4 mEq/L K, 2.7 mEq/L Ca, and 28 mEq/L lactate buffer (osmolality 273 mOsm/L, SID ~28 mEq/L).

Plasma-Lyte A : Contains 140 mEq/L Na, 98 mEq/L Cl, 5 mEq/L K, 3 mEq/L Mg, 27 mEq/L acetate, and 23 mEq/L gluconate buffer (osmolality 294 mOsm/L, SID ~50 mEq/L).

Myth Buster : The lactate buffer in Lactated Ringer's is sodium lactate, not lactic acid . In the liver, sodium lactate is metabolized into bicarbonate; it does not induce lactic acidosis or alter diagnostic serum lactate interpretations.

Landmark Trial Evidence

The SMART Trial ( Semler et al., NEJM 2018 ; n=15,802 ICU patients): Demonstrated that the use of balanced crystalloids compared to saline significantly reduced the 30-day composite incidence of Major Adverse Kidney Events within 30 days (MAKE30) —defined as in-hospital death, new renal replacement therapy, or persistent renal dysfunction (14.3% vs. 15.4%, p=0.04). In the septic subgroup (n=1,641), 30-day mortality was significantly lower in the balanced crystalloid group (25.2% vs. 29.4%).

The SALT-ED Trial ( Self et al., NEJM 2018 ; n=13,347 emergency department non-ICU patients): Demonstrated that balanced crystalloids significantly decreased MAKE30 compared to saline (4.7% vs. 5.6%, p=0.01).

Colloids and Albumin

Hydroxyethyl Starches (HES) : Strongly contraindicated in sepsis. Multiple large trials (6S, CHEST) proved that starch solutions increase mortality and the requirement for renal replacement therapy.

Human Albumin : The SSC 2021 guidelines suggest using albumin (5% or 20%) as an adjunct in patients who have received large volumes of crystalloids (>30-40 mL/kg) and remain in shock. Albumin expands intravascular volume more efficiently than crystalloids and scavenges reactive oxygen species without worsening renal failure.

Vasopressor, Inotropic & Corticosteroid Pharmacology VASOPRESSOR TITRATION HIERARCHY

┌─────────────────────────────────────────────────────────────┐
│ FIRST-LINE: NOREPINEPHRINE │
│ • Dose: 0.02 - 1.0+ mcg/kg/min │
│ • Alpha-1 (potent vasoconstriction) + Beta-1 (inotropic) │
│ • Target MAP >=65 mmHg; SOAP II: superior to dopamine │
└──────────────────────────────┬──────────────────────────────┘
│ If requiring escalating doses
▼
┌─────────────────────────────────────────────────────────────┐
│ SECOND-LINE: VASOPRESSIN (ARGIPRESSIN) │
│ • Dose: FIXED non-titratable 0.03 units/min │
│ • V1a receptor stimulation; restores endogenous deficiency │
│ • Spares adrenergic burden; do NOT titrate >0.03-0.04 U/min │
└──────────────────────────────┬──────────────────────────────┘
│ If MAP remains refractory
▼
┌─────────────────────────────────────────────────────────────┐
│ THIRD-LINE: EPINEPHRINE │
│ • Dose: 0.01 - 0.5 mcg/kg/min │
│ • Potent Alpha-1 + Beta-1/Beta-2; raises lactate (aerobic) │
└─────────────────────────────────────────────────────────────┘

SPECIAL CIRCUMSTANCES:

Myocardial Dysfunction / Hypoperfusion: ADD DOBUTAMINE (2.5-20 mcg/kg/min)
Refractory Shock (Norepi >=0.25 mcg/kg/min): ADD IV HYDROCORTISONE 200 mg/d
1. Norepinephrine (First-Line)

Receptor Affinity : Potent alpha-1 adrenergic agonist with modest beta-1 adrenergic activity and negligible beta-2 activity.

Hemodynamics : Increases systemic vascular resistance (SVR) and arterial tone, elevating MAP. Its modest beta-1 effect preserves stroke volume and cardiac output without excessive tachycardia.

The SOAP II Trial ( De Backer et al., NEJM 2010 ; n=1,679): Compared norepinephrine to dopamine in shock. Dopamine was associated with a twofold increase in severe arrhythmogenic events (20.7% vs. 12.4%, p<0.001) and a significant increase in 28-day mortality among patients with cardiogenic shock. In septic shock, norepinephrine proved significantly safer. Dopamine is now strictly restricted to rare cases of shock associated with bradycardia and minimal arrhythmia risk.

2. Vasopressin (Second-Line Adjunct)

Receptor Affinity : Stimulates vascular V1a receptors , activating phospholipase C and protein kinase C to induce calcium influx and smooth muscle contraction.

Mechanism in Sepsis : Septic shock induces an initial surge followed by rapid depletion of endogenous neurohypophyseal vasopressin stores, coupled with impaired autonomic baroreflexes. Exogenous vasopressin restores vascular tone via a non-adrenergic pathway.

Dosing Rule : Administered at a fixed, non-titratable dose of 0.03 units/min (some centers use 0.04 units/min) initiated when norepinephrine reaches moderate doses (typically 0.25 mcg/kg/min). Vasopressin reduces norepinephrine requirements and blunts adrenergic side effects ( VASST trial, NEJM 2008 ). It must never be titrated like a catecholamine ; doses >0.04 units/min induce intense coronary, mesenteric, and peripheral digital ischemia.

3. Epinephrine (Third-Line)

Receptor Affinity : High-affinity agonist across alpha-1, beta-1, and beta-2 receptors.

Role : Added to norepinephrine or used as salvage therapy when MAP remains refractory despite norepinephrine plus vasopressin.

Board Pearl : Epinephrine infusion stimulates skeletal muscle beta-2 adrenergic receptors, upregulating the Na+/K+-ATPase pump and enhancing aerobic glycolysis. This routinely generates an increase in blood lactate levels within the first 6 to 12 hours , which represents a benign drug effect rather than worsening tissue hypoperfusion or treatment failure.

4. Dobutamine (Inotropic Support)

Receptor Affinity : Potent beta-1 agonist with modest beta-2 and weak alpha-1 activity.

Indication : Administered (2.5 to 20 mcg/kg/min) in patients exhibiting persistent hypoperfusion (elevated lactate, low ScvO2 <70%, poor capillary refill, oliguria) despite adequate fluid resuscitation and achieving MAP ≥65 mmHg, or in patients with echocardiographic evidence of myocardial dysfunction (elevated filling pressures and depressed cardiac output).

5. Stress-Dose Corticosteroids in Refractory Shock

Indication : The SSC 2021 guidelines recommend intravenous corticosteroids only for patients with septic shock who require ongoing, escalating vasopressor therapy (e.g., norepinephrine or epinephrine dose ≥0.25 mcg/kg/min for at least 4 hours) despite adequate fluid resuscitation.

Dosing : Hydrocortisone 200 mg/day IV , administered either as 50 mg IV every 6 hours or as a continuous IV infusion of 8.3 mg/hour (200 mg over 24 hours).

Evidence Base : The APROCCHSS trial ( Annane et al., NEJM 2018 ) demonstrated that hydrocortisone plus fludrocortisone significantly decreased 90-day all-cause mortality (43.0% vs. 49.1%, p=0.03) and increased vasopressor-free days in refractory septic shock. The ADRENAL trial ( Venkatesh et al., NEJM 2018 ) showed faster shock resolution, reduced blood transfusion requirements, and shortened ICU length of stay.

Diagnostic Testing : Random cortisol levels and ACTH stimulation tests are not recommended ; therapy is initiated based solely on the clinical requirement for escalating vasopressors.

Assessment of Fluid Responsiveness & Hemodynamic Monitoring

While early fluid resuscitation is lifesaving, excessive fluid administration leads to interstitial edema, worsening gas exchange, intra-abdominal hypertension, prolonged mechanical ventilation, and increased mortality.

The Failure of Static Hemodynamic Measures

Central Venous Pressure (CVP) : CVP reflects right ventricular preload and thoracic compliance, not volume responsiveness. Systematic reviews show that CVP correlates poorly with changes in cardiac output (area under ROC curve ~0.56, equivalent to tossing a coin). The SSC guidelines strongly recommend against using CVP alone to guide fluid administration.

Dynamic Measures of Fluid Responsiveness

Dynamic parameters exploit respiratory-induced changes in intrathoracic pressure or reversible postural volume shifts to determine whether cardiac stroke volume will increase by ≥10% to 15% in response to fluid administration (the definition of a "fluid-responsive" patient). DYNAMIC FLUID RESPONSIVENESS MEASURES

1. PASSIVE LEG RAISE (PLR) TEST
Method: Shift from 45° semi-recumbent to flat with legs elevated 45°
Autotransfusion: Mobilizes ~300-500 mL venous blood from lower limbs
Evaluation: Requires REAL-TIME cardiac output / stroke volume monitor
Cutoff: Cardiac output increase >=10% confirms fluid responsiveness
Reversible: Hemodynamics return to baseline upon lowering legs

2. PULSE PRESSURE VARIATION (PPV) & STROKE VOLUME VARIATION (SVV)
Mandatory Requirements: Fully sedated, mechanically ventilated (TV >=8 mL/kg),
normal sinus rhythm, no spontaneous breathing efforts
Cutoff: PPV or SVV >12% - 13% indicates preload responsiveness

3. POINT-OF-CARE ULTRASOUND (POCUS)

Inferior Vena Cava (IVC) Respiratory Collapsibility:

Spontaneously breathing: >50% inspiratory collapse (Caval Index) suggests hypovolemia
Mechanically ventilated: >15-18% inspiratory distensibility indicates responsiveness
Echocardiography: Assess Left Ventricular Outflow Tract Velocity-Time Integral (LVOT VTI)